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Abstract 
Probiotics are live microbial feed supplement and can provide health benefit to the host if administered in 
sufficient amounts. The most predominant species that have been used as probiotic include Lactobacilli and 
bifidobacteria. Proper administration of probiotics could be efficient in the treatment of various disorders. 
However; their mechanism of action is poorly understood. The effects of probiotics may be classified in following 
modes: reinforcement of the intestinal mucosal barrier against pathogens, competition with pathogens for 
adherence to the mucosa and epithelium, competitive exclusion of pathogenic microorganisms, production of 
antimicrobial substances, modulation of the immune system and interference with quorum sensing signaling. 
Exploration of the clinical features of probiotic strains, their modes of action and investigation based on probiotic 
therapy may be beneficial in treatment of various diseases.. 
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According to the Food and Agriculture Organization of 
the United Nations (FAO) and the World Health 
Organization (WHO), probiotics are live 
microorganisms that can confer a health benefit to the 
host if administered in adequate amounts 
1
. The name 
probiotic comes from the Greek 'pro bios' which means 
'for life'. At the beginning of the 20th century, 
Probiotic was first conceptualized by the Russian 
Nobel Prize winner and father of modern immunology, 
Elie Metchnikoff 
2
. In 1965, the first introduction of 
probiotic term was reported by Lilly and Still wellin to 
describe ‘substances secreted by one microorganism 
which stimulate the growth of another 
3, 4
. In 1974 
Parker proposed that probiotics are organisms and 
substances which contribute to intestinal microbial 
balance 
5
. In 1989, Fuller introduced the modified 
definition of probiotic. According to the Fuller 
definition, probiotics are a live microbial feed 
supplement which beneficially affects the host by 
improving its microbial balance 
6
. According to 
definition of Salminen et al, in 1998, probiotics are 
foods which contain live bacteria which can be 
beneficial to health, whereas Marteau et al in 2002 
defined probiotics as microbial cell or components of 
microbial cells that have a beneficial effect on the 
health and well-being 
7, 8
. 
There are several characteristics for assessment of a 
good probiotic product. many investigators believe that 
the definition of an ideal probiotic is based on the 
following options: resistant to gastric acid digestion 
and to bile salts, high ability to multiply in the gut, 
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strong adhesive capability with the digestive tract of 
the host, lacking side effect; do not have pathogenic 
and toxic effect on host cells, durable enough, ability to 
reduce the pathogenic microorganisms 
9
. 
The most predominant species that have been used as 
probiotic bacteria are summarized in Table 1. 
However, probiotic bacteria can be also derived from 
the intestinal microbiota of healthy humans, nonhuman 
strains used in the fermentation of dairy products or 
species from genera such as Streptococcus, Bacillus 
and Enterococcus. Due to some of genera such as 
Streptococcus, Bacillus, and Enterococcus containing 
many pathogenic species there is some concerns about 
safety of such probiotics. Yeasts especially 






Table 1. Commercial probiotic microorganisms 
 
Lactobacillus species Bifidobacterium species Other bacteria 
L. acidophilus B. bifidum Bacillus cereus 
L. casei (rhamnosus) B. longum Escherichia coli 
L. johnsonii 
 
B. breve Saccharomyces cerevisiae 
L. bulgaricus B. infantis Enterococcus faecalis 
L. plantarum B. lactis  
L. reuteri B. adolescentis  
L. lactis   
 
Discussion 
A prebiotic is non-digestible food ingredients that 
beneficially affect the host by selectively stimulating 
the growth and activity of one species or a limited 
number of species in the colon. Oligosaccharides such 
as lactulose, galactooligosaccharides, inulin and 
fructooligosaccharides, are some of the prebiotics that 
are able to promote the growth and activities of 
probiotics.  Synbiotics refer to nutritional supplements 




Mechanisms of action of probiotics 
Probiotic bacteria have various effects on the host cells 
and are advocated for the prevention and treatment of a 
wide range of disorders. The main mode of probiotic 
actions include 1) enhancement of the epithelial barrier 
2) increased adhesion to intestinal mucosa and 
simultaneous inhibition of pathogen adhesion 3) 
competitive exclusion of pathogenic microorganisms 
4) production of anti-microbial substances 5) 
modulation of the immune system. Recent data exhibit 





Enhancement of the epithelial barrier 
 
Intestinal barrier in healthy individual consists of the 
mucous layer, antimicrobial peptides, secretory IgA 
and epithelial cells that form tight junctions 
15
. 
Disruption of the intestinal barrier function may result 
in enteric infections, celiac disease, some autoimmune 
diseases such as type1 diabetes and inflammatory 
bowel disease (IBD). Consumption of probiotic 




Intestinal barrier integrity may be increased by 
enhancing the expression of genes involved in tight 
junction signaling 
20
. Some of the probiotics are able to 
induce signaling pathway involved in tight junction. 
For instance, Lactobacilli modulate the regulation of E-
cadherin and β -catenin, in a T84 cell. Moreover, 
incubation of intestinal cells with lactobacilli 
modulates tight junction protein phosphorylation 
21
. 
Probiotics may also repair the barrier function after 
damage. Escherichia coli Nissle 1917 (EcN1917) not 
only counteract the disruptive effects of 
enteropathogenic E. coli (EPEC) but also restores 
mucosal integrity in Caco-2 cells. This effect is 
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achieved by increasing expression and repartition of 
tight junction proteins of the zonula-occludens (ZO-2) 
and altering protein kinase C signaling 
22
. In a TLR-
independent pathway, Probiotics can protect the 
integrity of the mucosal gut barrier against the 
destructive action of enteropathogenic Escherichia coli. 
Alteration in levels of pro-inflammatory cytokines can 
lead to intestinal permeability in intestinal disease such 
as IBD. Consumption of probiotic bacteria prevents 
cytokine-induced epithelial damage 
23, 17
. Soluble 
peptides secreted by Lactobacillus rhamnosus GG 
(LGG), p40 and p75 can prevent TNF-a-mediated cell 
apoptosis by activating the anti-apoptotic factor Akt 
and protein kinase B (PKB/Akt) and inhibiting the pro-




Induction of mucous secretion by probiotic bacteria 
reinforces barrier function and the exclusion of 
pathogens 
26
. Some of Lactobacillus species increases 




Probiotic strains can also release antimicrobial proteins 
(AMPs) such as α defensins, β defensins, cathelicidins, 
C-type lectins and ribonucleases from epithelial cells. 
These small proteins can stabilize intestinal barrier 
function 
28-32
. Defensins display antimicrobial activity 
against a wide range of bacteria fungi and viruses. 





Increased adhesion to intestinal mucosa 
Probiotic bacteria are able to adhere to epithelial cells, 
thereby, can block adherence of pathogens. The anti-
adhesive effect might be the result of competition 
between probiotic strains and pathogens for the same 




Several studies exhibited that different lactobacilli 
proteins promote mucous adhesions and bacterial 
surface adhesions mediate attachment to the mucous 
layer 
37, 38
. MUB (mucus-binding protein) produced by 
Lactobacillus reuteri and MapA (mucous adhesion- 
promoting protein) by L. reuteri and L. fermentum has 
been reported to mediate the binding to mucous 
38, 39
. 
Probiotic bacteria competitively inhibit adhesion of 
pathogenic bacteria. Lactobacillus GG and 
Lactobacillus plantarum 299V competitively inhibit the 





Competitive exclusion of pathogenic 
microorganisms 
Based on several reported researches, probiotic 
bacteria are able to exclude or reduce the growth of 
pathogens by one of following ways: creation of a 
hostile microenvironment, physical blocking of 
available bacterial receptor sites, production and 
secretion of antimicrobial substances and selective 
metabolites and competition for essential nutrients 
42
. 
Production of antimicrobial substances 
Antimicrobial substances produced by probiotics can 
lead to inhibition of pathogen replication. These 
components are almost always low-molecular-weight 
(LMW) compounds (< 1,000 Da). The most important 
of these LMW compounds are short chain fatty acids. 
Organic acids especially acetic acid and lactic acid 
inhibit the growth of Gram-negative bacteria 
43
. Also 
low-molecular-weight bacteriocins (LMWB) and high-
molecular-weight bacteriocins produced by lactobacilli 
can inhibit pathogen replication. Some of lactic acid 
bacteria (LAB) produce bacteriocins. Lactacin B is 
produced by L. acidophilus and plantaricin by L. 
plantarumandnisin 
45
. These bacteriocins have a 
narrow activity spectrum against related species such 
as other lactobacilli and taxonomically related Gram-
positive bacteria or broad activity spectrum against 
across genera such as Gram-positive and Gram-
negative bacteria as well as yeasts and molds 
46
. Some 
of the most probable mechanisms of bacteriocins are 
formation of pore in cell membrane and inhibition of 




Studies done on probiotic bacteria exhibited that some 
of them can produce antibacterial compounds. 
Lactobacillus reuteri can produce reuterin antibiotic 
that is a broad spectrum antibiotic which not only is 
active against Gram-positive and Gram-negative 




Intestinal bifidobacteria and lactobacilli also produce 
fatty acids such as conjugated linoleic acid (CLA) 
which is a potent anti-carcinogenic agent. CLA-
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producing strains also show an anti-obesity effect and 
the ability to modulate the fatty acid composition of the 
liver and adipose tissue of the host in mice model 
48, 49
. 
Finally, the production metabolite and derivatives of 
bile salts by some strains of probiotics can suppress the 
growth of fungi and other species of bacteria 
51, 52
. For 
instance, Lactobacillus can produce antifungal 
substances, such as benzoic acid, methylhydantoin, 




Probiotics and the immune system 
Probiotic bacteria can effect on numerous cell types 
involved in the innate and adaptive immune responses 
such as epithelial cells, dendritic cells, 
monocytes/macrophages, B cells, T cells, regulatory T 





Effects of Probiotic Bacteria on Dendritic Cells 
Dendritic cells (DCs) are antigen-presenting cells that 
act as messengers between the innate and the adaptive 
immune systems. Specialized functions of DC in 
intestine lead to induction of oral tolerance to dietary 
antigens by development regulatory T cells and IgA-
producing B cells through production of cytokines such 
as IL-10 and TGFβ 
56-59
. Probiotic bacteria can down-
regulate Th1 response and inhibit the production of 






Effects of Probiotic Bacteria on B Lymphocytes 
Administration of L. rhamnosus GG to children with 
acute gastroenteritis increased a nonspecific humoral 
immune response by an enhancement in IgG, IgA, and 
IgM secretion from circulating lymphocytes 
62
. In 
vaccination trial, the effects of probiotic bacteria on B 
lymphocytes have been proven. Studies indicate that 
combination of L. rhamnosus GG and Salmonella 





Effects of Probiotic Bacteria on Natural Killer (NK) 
Cells 
More recently, in an animal study it have been proven 
that L. casei ssp. casei with prebiotic such as dextran 
enhanced the NK cell activities in spleen mononuclear 
cells of BALB/c mice and its oral administration 
increased production of IL-12 in human blood 
mononuclear cells 
64
. Secretion of IL-22 by NK cells 
has anti-inflammatory effects on epithelial cells in vitro 
65
. In addition, activity of NK cells will increase with 




Effects of Probiotic Bacteria on T cells 
T cell response is mainly controlled by interactions 
between DC and T cells. Assessment of effect 
monocyte-derived dendritic cell cultured with L. 
rhamnosus exhibited that T-cell proliferation and T-
cell cytokine production, particularly IL-2, IL-4, and 
IL-10 had decreased dramatically 
67
. 
Interference with signaling factor of quorum 
sensing 
Bacteria communicate with each other and their 
surrounding environment through chemical signaling 
molecules that are called auto-inducers. This 
phenomenon is known as quorum sensing (QS) that 
can measure the population density, nutrient 
concentration and other ecological characteristics. In 
addition to, QS can control the gene expression of the 




Probiotic bacteria such as lactobacillus, 
bifidobacterium and B.cereus strains can produce auto-
inducers that can control virulence gene expression in 
numerous microorganisms. Lactobacillus acidophilus 
La-5 secretes a compound that reduces the production 
of auto-inducer by E. coli O157 and through it, leads to 
significant reduction in the transcription of genes 
involved in colonization 
70
. Recently, many studies 
have reported similar results for B. cereus and B. toyoi 
71, 72
. 
Applications of probiotics 
In the past century the beneficial roles of 
nonpathogenic bacteria in the establishment of health 
were described. Recently it is proved that there are 
clinical benefits to use specific nonpathogenic 
organisms and also there is strong evidence for their 
efficacy in some clinical scenarios. Considering 
beneficial roles of probiotics, they are now widely used 
in many countries by consumers and in clinical practice 
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Diarrheal diseases 
Diarrhea is defined as the passage of 3 or more 
unformed stools for at least 2 consecutive days. 
Probiotics are able to protect the host against bacterial 
toxins and in this way impede diarrhea. L. casei 
rhamnosus (Lcr35) is found to inhibit colonization of 
large variety of pathogens in Caco-2 cell line and 
therefore prevent traveler's diarrhea 
73
. 
Bifidobacteriumlactis HN019 reduced the severity of 
diarrhea associated with both rotavirus and E. coli in 
pigs. This effect is attributed to the increase of 
immune-mediated protection 
74
. A meta-analysis done 
on probiotics exhibited that Saccharomyces boulardii 
and the bacterium Lactobacillus acidophilus in 
combination with L. bulgaricus, L. rhamnosus strain 
GG are effective in prevention of antibiotic-associated 
diarrhea. Another meta-analysis study done on 
probiotic bacteria showed that Lactobacillus species, 
Enterococcus species, and S boulardii are effective in 
the treatment of infective diarrhea in both adults and 
children (00). The preventive effect of Lactobacillus 
GG on antibiotic-associated diarrhea (AAD) has been 




Saccharomyces boulardii is effective in prevention and 
decrease of recurrent C. difficile infection (CDI). The 
effect of S. boulardii on C. difficile toxin in rats and 
human colonic mucosa is probably due to proteolytic 
digestion of toxins by secretion of protease. Although, 
they are used as a preventive and therapeutic measure 
but their role in treatment and prevention of CDI 
remains controversial. The best studied probiotic 
agents in CDI are Saccharomyces boulardii and 
Lactobacillus. Several studies shown that mixtures of 
probiotics can be useful in treatment and prevention of 




Urinary tract infections 
There is a close correlation between the loss of the 
normal microbiota of genital tract, especially 
Lactobacillus species, and an increased incidence of 
UTIs. The role of probiotics in prevention of UTI is 
obvious 
78
. Lactobacillus plantarum and Lactobacillus 
rhamnosus inhibit the adherence of E. coli to the 
gastrointestinal (GI) tract wall by inducing the 
production of mucin and leading to inhibition of the 
adhesion of pathogens 
79
. Recent research has shown 
that two probiotics strains, Lactobacillus acidophilus 
PXN35 and Lactobacillus plantarum PXN47 have 
good anti-bacterial effects in inhibiting E. coli growth 
80
. In study performed by Kontiokari et al. in 2003, 
they showed that consumption of fermented milk 
products containing probiotic bacteria more than three 
times a week was associated with a decreased risk of 
recurrent UTIs (RUTIs) 
81
.When Lactobacillus 
fermentum orally administer with low doses of 
ampicillin, was effective in the treatment of E. coli 




Helicobacter pylori infections 
During recent years, several studies in order to assess 
probiotics effect in the treatment of H. pylori infections 
have been done 
83
. In vitro studies demonstrated that 
strains of lactobacilli, bifidobacteria and B. subtilis 
inhibit the growth or the adhesion of H. pylori to 
mucus cells 
84-86
. In mice model, Lactobacillus 





The vaginal microbiota of healthy women consists of a 
wide variety of anaerobic and aerobic bacterial genera 
and species dominated by the genus Lactobacillus. 
Lactobacillus especially during pregnancy helps to 
maintain the natural healthy balance of the vaginal 
microbiota. Nad thereby decreases the rate of bacterial 
vaginosis (BV) and aerobic vaginitis (AV). In a study 
conducted by Hilton, oral administration of L. 
johnsonii effectively decreased candida vaginitis 
88
. 
The production of hydrogen peroxide and lactic acid by 
lactobacilli contribute to reduction of pH and may 





Small peptides and amino acids produced by some 
bacteria are able to induce allergic reactions. Several 
investigators have shown that imbalance between 
bifidobacteria and clostridia can lead to allergies 
84
. 
Enzymes derived from L. casei GG degrade Small 
peptides and amino acids, in result it will produce 
molecules with inhibitory effects on lymphocyte 
proliferation 
91
. Mechanisms of anti-allergic probiotic 
bacteria include increasing intestinal barrier integrity, 
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modulation of the immune system through the 
production of inflammatory cytokines or enhancement 
of specific IgA responses and degradation of food 




Lactose intolerance (LI), also known as lactose 
malabsorption is the most common type of 
carbohydrate malabsorption. Due to low levels of 
lactase enzyme activity in patients, they are not able to 
digest lactose into glucose and galactose. Intensive 
intestinal distress with characteristic bloating, 
flatulence and abdominal pain could appear 30- 
minutes to 2 hours after consumption of food products 
containing lactose disaccharide. Lactases produced by 
L. acidophillis and Lactobacillis delbrlleckii ssp. 
blilgaricus by β-galactoside galactohydrolase (β-gal) 
and LactococcliSlactics ssp. lactis and Lactococcus 
lactis ssp crenzoris by β-D-phosphogalactoside 
galactohydrolase (β--P-gal) are able to hydrolyze and 
ease absorption of lactose. The production of hydrogen 
in breath is an indicator of bacterial metabolism of 





Several studies showed that the reduction of serum 
cholesterol can be created by oral administration of L. 
johnsonii and L. reuterii in pigs. Probiotic bacteria can 
decrease blood cholesterol level by cholesterol 
absorption, de-conjugation of bile acids through 
bacterial hydrolysis, attachment of cholesterol to 






There are claims for anti-cancer activity of probiotics. 
Lactobacillus, Bifidobacteria and E. coli Nissle 1917 
strains have anti-mutagenic activities due to ability to 
metabolize and inactivate compounds of mutagen 
95
. 
The anticancer effects of probiotics probably are due to 
several mechanisms such as inhibition of 
procarcinogen transformation to active carcinogens, 
inactivation of mutagenic compounds, production of 
anti-mutagenic compounds, suppression of the growth 
of pro-carcinogenic bacteria, reduction of the 
absorption of mutagens from the intestine and 




According to the clinically proven benefits of 
probiotics it is clear that probiotics can be used for the 
prevention of various diseases and even their 
management. Therefore, it is possible to conceptualize 
the use of probiotics due to their low cost, decrease in 
antibiotic resistance, modulation of immune system 
and inhibition of pathogens providing good alternative 
over the antibiotics.  
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